AZN vs UPB
AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline. UPB: Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class TSLP receptor antagonist designed to offer superior efficacy and convenient quarterly dosing for severe respiratory diseases.
Side-by-side fundamentals
| Metric | AZN | UPB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $158.78 | $4.55 | |
| Market cap | $181.5B | $249M | |
| P/E as of 2026-09-03 | 23.44 | n/a | |
| Net margin FY2025, SEC XBRL | +17.4% | -5026.0% | AZN higher |
| Gross margin FY2025, SEC XBRL | +81.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +23.4% | -5618.8% | AZN higher |
| ROE FY2025, SEC XBRL | +21.0% | -42.2% | AZN higher |
| ROA FY2025, SEC XBRL | +9.0% | -40.5% | AZN higher |
| Debt / equity as of 2026-09-03 | 0.64 | 0.00 | UPB lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.6% | +13.2% | UPB higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +9.5% | AZN higher |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.34 | 1.12 | |
| 1-year return as of 2026-10-08 close | -7.0% | -76.0% | AZN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.